It holds your hands through the foundation of Rome, with excessive concern dedicated to the Aeneid, to the rise of the republic and the imperial period, then of Christianity and the splintering of the ...

Regulus (RGLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it ...

SAN DIEGO, March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

In December 2024, Regulus met with the FDA for an End-of-Phase 1 meeting where they reached alignment on the acceptability of the program's CMC, non-clinical and clinical pharmacology plans and ...

In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs ...